🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean

Recruitingn/aAges 9 Years - 17 YearsAllUniversity Hospital Center of Martinique
NCT04839757 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever / dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population). Dengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region. In order to

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
CHILDREN Inclusion Criteria for children: * Any child aged 9 to 17 years presenting to one of the hospital departments participating in the study at the University Hospitals of Martinique or Guadeloupe * Need to take a blood sample or place a peripheral venous line for the management of the child * Residence in Martinique or Guadeloupe since at least one year * Information on the study given to the child and his/her parent or legal guardian * Collection of the parent's or legal guardian's non-objection to the child's participation Exclusion Criteria for children: * Presence of fever or suspected acute infection * Presence of an immune deficiency or any other dysimmune condition PARENTS Parental inclusion criteria ("vaccine acceptability" survey) * Collection of the parent's or legal guardian's non-objection to participate in the Dengvaxia® vaccine acceptability survey * Comprehension of spoken and written French Non-inclusion criteria for parents (vaccine acceptability survey) \- None of the above
💊

What it tests

  • Not listed
📍

Where

1 site
Martinique University Hospital Center
Fort-de-France, Martinique
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy